Randomized placebo-controlled trial of the bradykinin B 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial

William R. Lumry, H. Henry Li, Robyn J. Levy, Paul C. Potter, H. Farkas, Dumitru Moldovan, Marc Riedl, Hongbin Li, Timothy Craig, Bradley J. Bloom, Avner Reshef

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B 2 receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II). To investigate icatibant efficacy and safety in subjects with acute HAE attacks. Subjects with moderate to very severe cutaneous or abdominal symptoms received icatibant (n = 43) or placebo (n = 45). Five subjects with laryngeal (mild-to-moderate) first attacks received icatibant (n = 3) or placebo (n = 2), and 5 subjects with severe laryngeal first attacks received open-label icatibant. Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P

Original languageEnglish
Pages (from-to)529-537
Number of pages9
JournalAnnals of Allergy, Asthma and Immunology
Volume107
Issue number6
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Hereditary Angioedemas
Angioedema
Bradykinin
Randomized Controlled Trials
Placebos
Therapeutics
Skin
icatibant
Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Randomized placebo-controlled trial of the bradykinin B 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema : The FAST-3 trial. / Lumry, William R.; Li, H. Henry; Levy, Robyn J.; Potter, Paul C.; Farkas, H.; Moldovan, Dumitru; Riedl, Marc; Li, Hongbin; Craig, Timothy; Bloom, Bradley J.; Reshef, Avner.

In: Annals of Allergy, Asthma and Immunology, Vol. 107, No. 6, 12.2011, p. 529-537.

Research output: Contribution to journalArticle

Lumry, William R. ; Li, H. Henry ; Levy, Robyn J. ; Potter, Paul C. ; Farkas, H. ; Moldovan, Dumitru ; Riedl, Marc ; Li, Hongbin ; Craig, Timothy ; Bloom, Bradley J. ; Reshef, Avner. / Randomized placebo-controlled trial of the bradykinin B 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema : The FAST-3 trial. In: Annals of Allergy, Asthma and Immunology. 2011 ; Vol. 107, No. 6. pp. 529-537.
@article{32164f0f53134124a04025034bdca934,
title = "Randomized placebo-controlled trial of the bradykinin B 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial",
abstract = "The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B 2 receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II). To investigate icatibant efficacy and safety in subjects with acute HAE attacks. Subjects with moderate to very severe cutaneous or abdominal symptoms received icatibant (n = 43) or placebo (n = 45). Five subjects with laryngeal (mild-to-moderate) first attacks received icatibant (n = 3) or placebo (n = 2), and 5 subjects with severe laryngeal first attacks received open-label icatibant. Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50{\%} or more reduction in symptom severity (2.0 vs 19.8 hours; P",
author = "Lumry, {William R.} and Li, {H. Henry} and Levy, {Robyn J.} and Potter, {Paul C.} and H. Farkas and Dumitru Moldovan and Marc Riedl and Hongbin Li and Timothy Craig and Bloom, {Bradley J.} and Avner Reshef",
year = "2011",
month = "12",
doi = "10.1016/j.anai.2011.08.015",
language = "English",
volume = "107",
pages = "529--537",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "6",

}

TY - JOUR

T1 - Randomized placebo-controlled trial of the bradykinin B 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema

T2 - The FAST-3 trial

AU - Lumry, William R.

AU - Li, H. Henry

AU - Levy, Robyn J.

AU - Potter, Paul C.

AU - Farkas, H.

AU - Moldovan, Dumitru

AU - Riedl, Marc

AU - Li, Hongbin

AU - Craig, Timothy

AU - Bloom, Bradley J.

AU - Reshef, Avner

PY - 2011/12

Y1 - 2011/12

N2 - The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B 2 receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II). To investigate icatibant efficacy and safety in subjects with acute HAE attacks. Subjects with moderate to very severe cutaneous or abdominal symptoms received icatibant (n = 43) or placebo (n = 45). Five subjects with laryngeal (mild-to-moderate) first attacks received icatibant (n = 3) or placebo (n = 2), and 5 subjects with severe laryngeal first attacks received open-label icatibant. Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P

AB - The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B 2 receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH deficiency or dysfunction (type I/II). To investigate icatibant efficacy and safety in subjects with acute HAE attacks. Subjects with moderate to very severe cutaneous or abdominal symptoms received icatibant (n = 43) or placebo (n = 45). Five subjects with laryngeal (mild-to-moderate) first attacks received icatibant (n = 3) or placebo (n = 2), and 5 subjects with severe laryngeal first attacks received open-label icatibant. Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P

UR - http://www.scopus.com/inward/record.url?scp=82955233701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955233701&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2011.08.015

DO - 10.1016/j.anai.2011.08.015

M3 - Article

C2 - 22123383

AN - SCOPUS:82955233701

VL - 107

SP - 529

EP - 537

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 6

ER -